Colon cancer is the third most common cause of death worldwide. Its onset is frequently a progression from a pathology known as colon adenopolyposis. No successful pharmacological approach exists and colectomy still remains the main option.
CM&D Pharma’s unique colon protector Eviendep is intended to slow down the progression of polyps to colon cancer, and to prevent their reoccurrence following removal. Early data published in Carcinogenesis shows a protective effect of Eviendep and suggests its use as a ‘potential approach against colorectal cancer development’. Launch is expected in 2011.
